Product menu

VISUAL OF AN OLDER MALE PATIENT

Patient profiles

Meet patients who may be suitable for the AREXVY vaccine.

PREV
NEXT
IMAGE OF AN OLDER AFRICAN-AMERICAN FEMALE PATIENT

Eve, age 65

Medical history:

  • No underlying conditions
  • Has high blood pressure and high cholesterol

Lifestyle:

  • She eats a healthy diet to help manage her overall health
  • Stays active by playing with her grandchildren

Interaction with HCP:

  • Diligent about annual physicals and is proactive about her health, including keeping up to date on her vaccinations

Start the conversation about AREXVY because:

  • She is at risk of RSV disease due to her age and is eligible for vaccination.1-3

Fictitious patient. May not be representative of the general population.

IMAGE OF AN OLDER WHITE MALE PATIENT

Darrell, age 69

Medical history:

  • Currently managing COPD

Lifestyle:

  • Lives a sedentary lifestyle and doesn’t prioritize exercise
  • Has gotten less mobile with age

Interaction with HCP:

  • Occasional visits with his respirologist for COPD checkups

Start the conversation about AREXVY because:

  • He is at risk of RSV disease due to his age and other risk factors, including COPD, and is eligible for vaccination.1-3

Fictitious patient. May not be representative of the general population.

COPD = chronic obstructive pulmonary disease.

IMAGE OF AN OLDER ASIAN MALE PATIENT

Kenzo, age 73

Medical history:

  • Type 2 diabetes

Lifestyle:

  • Enjoys travelling with his wife
  • Keeps his weight down and lives healthily

Interaction with HCP:

  • Goes to the doctor regularly to review his A1C levels

Start the conversation about AREXVY because:

  • He is at risk of RSV disease due to his age and other risk factors, including diabetes, and is eligible for vaccination.1-4

Fictitious patient. May not be representative of the general population.

IMAGE OF AN OLDER ASIAN MALE PATIENT

Leah, age 66

Medical history:

  • Currently managing chronic heart failure

Lifestyle:

  • Helps to care for her older parents
  • Often too busy to exercise or eat well

Interaction with HCP:

  • Doesn’t always prioritize her health and sometimes misses appointments

Start the conversation about AREXVY because:

  • She is at risk of RSV disease due to her age and other risk factors, including chronic heart failure, and is eligible for vaccination.1-3

Fictitious patient. May not be representative of the general population.

Patient resources

Find additional AREXVY resources for your patients.

RESOURCES FOR YOUR PATIENTS

CHECKMARK ICON

Recommendations

Review recommendations on RSV vaccination for adults aged ≥60 years.4-7

LEARN MORE

ICON OF A MAGNIFYING GLASS

See AREXVY efficacy data 

Efficacy of AREXVY against RSV-associated LRTD in adults 60 years and older was evaluated in Study AReSVi-006.1 

LEARN MORE

References:

  1. AREXVY Product Monograph, GlaxoSmithKline Inc.
  2. Government of Canada. Respiratory syncytial virus (RSV): for health professionals. Available at: https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html. Accessed February 10, 2023.
  3. Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV): for healthcare providers. Available at: https://www.cdc.gov/rsv/clinical/index.html. Accessed September 28, 2023.
  4. Melgar M, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. Morb Mortal Wkly Rep 2023;72:793–801.
  5. Government of Canada. Respiratory syncytial virus (RSV): Canadian Immunization Guide. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html. Accessed January 26, 2024.
  6. American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes – 2024. Diabetes Care 2024:47(Suppl.1):S52–76.
  7. Global Initiative for Chronic Obstructive Lung Disease 2024 Report. Available at:
https://goldcopd.org/wp-content/uploads/2024/01/GOLD-2024_v1.2-11Jan24_WMV-1.pdf. Accessed February 8, 2024.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

104605 | 07/24